Phosphodiesterase 4D (PDE4D) catalytic domain (PDE4D-CD)

Phosphodiesterase 4D (PDE4D) is a member of the PDE4 family of enzymes that specifically hydrolyze cyclic adenosine monophosphate (cAMP), a critical second messenger in various signaling pathways (UniProt: P53368). The catalytic domain of PDE4D is the highly conserved region responsible for the enzymatic conversion of cAMP to 5'-AMP, containing essential metal-binding sites and a glutamine switch for substrate recognition (PMID: 25613532). By regulating cAMP levels, PDE4D plays a pivotal role in modulating inflammatory responses, airway smooth muscle contraction, and cognitive functions (PMID: 15190204). In the context of drug discovery, the catalytic domain is the primary target for small-molecule inhibitors designed to treat conditions such as COPD, psoriasis, and cognitive impairment (DrugBank: DB01156). However, non-selective inhibition of the PDE4D catalytic domain is frequently associated with dose-limiting side effects, most notably nausea and emesis, which are thought to be mediated by PDE4D in the area postrema of the brain (PMID: 24451911). Recent therapeutic strategies focus on developing allosteric modulators or isoform-selective inhibitors to improve the therapeutic index and minimize these adverse effects (ClinicalTrials.gov: NCT02840279).

Other names

cAMP-specific 3',5'-cyclic phosphodiesterase 4D catalytic domainPDE4D catalytic coreDPDE3STRK1Phosphodiesterase 4D

Competitive inhibition of cAMP hydrolysis by binding to the catalytic site, thereby increasing intracellular cAMP levels and activating downstream signaling pathways like PKA and CREB.